



Opinion

Ecological Constraint and Functional Response in Microbiome-informed Integrative Medicine



Rebecca Lewandowski*

Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ, USA

Received: May 06, 2026 | Revised: May 21, 2026 | Accepted: May 28, 2026 | Published online: June 26, 2026

The clinical integration of microbiome science has progressed rapidly, particularly within integrative medicine, where stool testing and lifestyle-based microbiome interventions are increasingly used to guide patient care. Advances in sequencing technologies now permit detailed taxonomic characterization of microbial communities, yet most clinically accessible microbiome assessments still rely on stool, a distal luminal readout that only partially captures the spatial organization of the gastrointestinal tract.^{1–3} As a result, the interpretive frameworks required to translate microbiome data into clinically meaningful contexts and decisions remain incomplete, and microbiome information is often applied in ways that exceed the strength of current evidence.

A persistent issue is the tendency to treat detection as equivalent to meaning. Compositional differences identified through stool analysis are often interpreted as dysbiosis, even though relative abundance alone cannot establish altered metabolic output, functional activity, strain-level behavior, virulence potential, host interaction, or clinical consequence.^{4–7} Even so, interventions are often designed as though restoring an assumed optimal microbial balance were the therapeutic goal. In that implicit model, microbial composition becomes the primary therapeutic target, and lasting compositional change serves as a proxy for clinical success. That interpretive reflex makes microbiome change easy to see, but not necessarily easy to understand.

This model is difficult to reconcile with the biology of the gut microbiome, where healthy individuals show substantial interindividual variation and personalized longitudinal stability, and where functional outputs may be maintained across distinct community structures because microbial pathways are distributed across multiple taxa.^{4,5,8} These observations suggest that compositional change is neither necessary nor sufficient for clinical benefit.

The microbiome is better understood as a regulated ecological system in which resistance to perturbation may reflect resilience

rather than therapeutic failure.^{8–10} From this perspective, stool taxonomy is most useful as ecological context for intervention, and response is best judged through functional and host-relevant change rather than compositional movement alone. This article proposes a clinical framework for microbiome-guided integrative care in which stool-based data are interpreted as partial ecological context, interventions are matched to system behavior, and response is evaluated through functional and host-relevant outcomes rather than taxonomic change alone.

Meaningful interpretation of microbiome data requires attention to comparator, biological layer, and clinical context. Stool taxonomy can indicate who is present, but it does not establish what the community is doing, whether a signal is clinically meaningful, or whether a change exceeds expected biological variation.^{4,5,7} Major perturbations, moderate lifestyle interventions, and ordinary temporal fluctuation therefore should not be interpreted on the same scale.^{8,11,12} Clinically, microbiome change becomes useful only when read in relation to functional consequence and host-relevant response.¹¹

If stool taxonomy is not the endpoint of care, its clinical role must be reframed. Rather than prescribing microbial correction, stool provides only a partial ecological representation of the gastrointestinal tract. It reflects a distal luminal output rather than the full spatial and host-facing organization of the gut, but it can still offer useful context when interpreted carefully.^{1,3–5}

A stool profile is therefore better understood as a constraint map than as a therapeutic directive. Patterns of diversity, dominance, stability, and ecological openness may suggest ecological flexibility or resistance.^{9,13,14} Stable, diverse profiles may indicate greater niche occupation and functional redundancy, whereas volatile or low-diversity profiles may suggest reduced buffering and greater susceptibility to perturbation.^{12–16} These categories should be treated as interpretive heuristics rather than validated clinical classifications.

The clinical value of stool data lies in helping the clinician anticipate how intervention should proceed. A stable system may call for functional modulation, whereas a fragile system may first require stabilization before optimization. The value of the stool profile lies not in identifying what to force, but in helping calibrate how gently to begin, how sequentially to proceed, and how much disruption the system is likely to tolerate. This clinician-oriented workflow is summarized in [Figure 1](#), and the interpretation of

*Correspondence to: Rebecca Lewandowski, Department of Molecular and Cellular Biology, University of Arizona, 1401 E University Blvd, Tucson, AZ 85721, USA. ORCID: <https://orcid.org/0009-0009-3542-5125>. Tel: +1-215-499-8667, E-mail: lewandowskir@arizona.edu

How to cite this article: Lewandowski R. Ecological Constraint and Functional Response in Microbiome-informed Integrative Medicine. *Future Integr Med* 2026;5(3):165–169. DOI: 10.14218/FIM.2026.00010.




Fig. 1. Clinician-oriented workflow for microbiome-informed care. Baseline assessment integrates stool ecological patterning, metabolic or functional readouts, and patient history with clinical context to define a constraint map of the treatment terrain. Intervention is then matched to the inferred system state using measured, staged strategies, and follow-up uses clinical and functional response to refine care over time. The workflow emphasizes response-guided interpretation rather than taxonomic change alone. The figure was generated with the assistance of FigureLabs (AI image generation platform integrating multiple models), then reviewed and edited by the author for scientific accuracy, clarity, and final content. SCFAs, short-chain fatty acids.

stability and change is summarized in [Figure 2](#).

Once stool is interpreted as a constraint map, stability should not be treated as non-response by default. A stable microbiome may be protective, neutral, or maladaptively persistent depending on host context and functional outputs.^{7,9,10} If symptoms, metabolites, inflammatory features, barrier-associated biology, or tolerance improve while taxonomy remains stable, the result may represent functional success within a resilient system rather than failure to remodel the microbiome.^{5,17,18} Conversely, if stability accompanies persistent dysfunction or poor recovery capacity, it may reflect ecological lock-in rather than resilience. The goal is neither change nor stability for its own sake, but adaptive host-microbe function.

Intervention should therefore be matched to system behavior rather than to an abstract expectation of taxonomic change. In a stable, diverse microbiome, colonization resistance, niche occupation, and functional redundancy may limit durable compositional change even when host-relevant function can still be modified.^{4,5,13} In fragile systems, compositional change may be easier to produce but harder to interpret.^{9,12,16} Fecal microbiota transplantation remains an important boundary case in which deliberate community remodeling can be therapeutically central, particularly in recurrent *Clostridioides difficile* infection, but that logic should not be generalized to microbiome-informed care more broadly.^{19,20} [Figure 2](#) provides a conceptual matrix for interpreting stability and change across resilient, fragile, responsive, and maladaptively persistent system states.

The evaluation of microbiome-directed interventions has traditionally emphasized persistence, particularly in the context of probiotics, where post-intervention detection of the introduced organism is often treated as evidence of success. Yet colonization outcomes for exogenous microbes are shaped by baseline community structure, microbial interactions, and host context, making persistence an ecological result rather than a universal marker of therapeutic effect.^{17,21,22} Many microbiome-associated effects may instead occur through transient metabolic activity, substrate transformation, host signaling, immune modulation, or changes in luminal conditions, meaning that an intervention may be biologically active even when it does not durably colonize.

Probiotic studies illustrate this problem clearly. Colonization after probiotic administration is highly individualized, and engraftment appears to depend on host and baseline microbiome features rather than product exposure alone.²¹ To interpret these outcomes solely through detection is to miss the more clinically relevant question: whether the intervention changed what the system does in a meaningful way.

A function-centered approach instead asks whether intervention altered metabolites, inflammatory tone, barrier-associated biology, bowel patterns, tolerance, or symptoms in clinically meaningful ways. These questions align more closely with the mechanisms through which gut microbial activity plausibly affects host physiology.^{18,23,24} Microbial function does not map cleanly onto taxonomy, so limited taxonomic movement does not rule out meaningful biological effect. In this model, transient microbial or




Fig. 2. Interpreting microbiome stability and change by ecological resistance and host compatibility. The matrix separates two features that are often conflated: how readily a microbiome changes after perturbation and whether its current function appears compatible with host health. Responsive systems may be modifiable without being robust, while resilient systems may preserve function despite limited compositional change. Fragile systems may require stabilization before optimization, whereas maladaptively persistent systems may resist change while maintaining dysfunction. The figure was generated with the assistance of FigureLabs (AI image generation platform integrating multiple models), then reviewed and edited by the author for scientific accuracy, clarity, and final content.

substrate-driven activity may still be clinically meaningful even when durable colonization does not occur.^{17,25,26}

Non-persistence should therefore not be dismissed reflexively. A probiotic organism may fail to appear in follow-up stool testing while symptoms, tolerance, or functional markers improve.^{17,21} Conversely, persistence without host-relevant benefit should not be treated as clinical success.

For integrative medicine, the practical implication is that intervention evaluation should be layered. Taxonomy may remain useful, but it should be interpreted alongside functional and clinical readouts. The key is not whether the microbiome has been forcibly remodeled, but whether the host–microbe system performs better under real clinical conditions.

Evaluating interventions by function rather than persistence aligns assessment more closely with mechanism. Microbiome-directed care does not always need to install new organisms, remodel community structure, or overcome colonization resistance. In many cases, the more clinically relevant goal is to introduce inputs that temporarily and meaningfully improve system performance within the ecological constraints already present. Under those conditions, response becomes informative in its own right, including in how the order of interventions is interpreted.

Sequential intervention gives response data greater interpretive value. When diet, probiotics, supplements, and lifestyle changes are introduced simultaneously, clinical improvement may occur, but the mechanism becomes harder to interpret. When interventions are introduced in stages, the magnitude, timing, durability, and recovery pattern of response can reveal how the host–microbe system behaves under specific inputs.^{27,28} In this sense, intervention becomes a form of physiological probing. It

shifts the clinical question from “What is present?” to “How does this system respond?” and makes response itself part of the interpretive framework.

The clinical value of this approach lies in making microbiome data more biologically meaningful and clinically interpretable. No microbiome readout is inherently meaningful. Its significance depends on comparator, scale, biological layer, and clinical context.¹¹ Within that logic, stool taxonomy is most useful as ecological context for intervention rather than as a prescriptive endpoint.

A stable microbiome should not automatically be treated as requiring correction, and a readily shifting microbiome should not be assumed to be more resilient.^{9,10,12,16} Similarly, persistence is not a universal marker of success, nor is taxonomic movement a sufficient proxy for benefit. Diet, probiotics, fermented foods, fiber, exercise, sleep timing, and related integrative inputs may act through altered substrate availability, metabolite production, immune signaling, epithelial interactions, transit, or circadian organization rather than durable compositional remodeling alone.^{21,23,29,30}

Baseline stool data may be useful, but response patterns often provide the more actionable signal because they reveal how a given ecology behaves under perturbation.^{27,28} Used this way, microbiome-informed care becomes a disciplined way of reading biological context, intervening with greater precision, and learning from response over time. It allows stool data to inform judgment without pretending to dictate it.

Acknowledgments

The author acknowledges the University of Arizona, Tucson, AZ,

USA, for institutional access to library resources, staff support, and related research infrastructure through an appointment as a Designated Campus Colleague.

Funding

This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

The author declares that there is no conflict of interest related to this work.

Author contributions

RL is the sole author of the manuscript.

References

- [1] Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* 2016;14(1):20–32. DOI: 10.1038/nrmicro3552, PMID: 26499895.
- [2] Tang Q, Jin G, Wang G, Liu T, Liu X, Wang B, *et al.* Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices. *Front Cell Infect Microbiol* 2020;10:151. DOI: 10.3389/fcimb.2020.00151, PMID: 32328469.
- [3] Shalon D, Culver RN, Grembi JA, Folz J, Treit PV, Shi H, *et al.* Profiling the human intestinal environment under physiological conditions. *Nature* 2023;617(7961):581–591. DOI: 10.1038/s41586-023-05989-7, PMID: 37165188.
- [4] Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012;486(7402):207–214. DOI: 10.1038/nature11234, PMID: 22699609.
- [5] Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med* 2016;8(1):51. DOI: 10.1186/s13073-016-0307-y, PMID: 27122046.
- [6] Bruijning M, Ayroles JF, Henry LP, Koskella B, Meyer KM, Metcalf CJE. Relative abundance data can misrepresent heritability of the microbiome. *Microbiome* 2023;11(1):222. DOI: 10.1186/s40168-023-01669-w, PMID: 37814275.
- [7] Ma Z, Zuo T, Frey N, Rangrez AY. A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation. *Signal Transduct Target Ther* 2024;9(1):237. DOI: 10.1038/s41392-024-01946-6, PMID: 39307902.
- [8] Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, *et al.* The long-term stability of the human gut microbiota. *Science* 2013;341(6141):1237439. DOI: 10.1126/science.1237439, PMID: 23828941.
- [9] Fassarella M, Blaak EE, Penders J, Nauta A, Smidt H, Zoetendal EG. Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. *Gut* 2021;70(3):595–605. DOI: 10.1136/gutjnl-2020-321747, PMID: 33051190.
- [10] Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* 2012;489(7415):220–230. DOI: 10.1038/nature11550, PMID: 22972295.
- [11] Anthony WE, Wang B, Sukhum KV, D'Souza AW, Hink T, Cass C, *et al.* Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. *Cell Rep* 2022;39(2):110649. DOI: 10.1016/j.celrep.2022.110649, PMID: 35417701.
- [12] Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. *Nat Rev Microbiol* 2023;21(12):772–788. DOI: 10.1038/s41579-023-00933-y, PMID: 37491458.
- [13] Spragge F, Bakkeren E, Jahn MT, B N Araujo E, Pearson CF, Wang X, *et al.* Microbiome diversity protects against pathogens by nutrient blocking. *Science* 2023;382(6676):eadj3502. DOI: 10.1126/science.adj3502, PMID: 38096285.
- [14] Ramond P, Galand PE, Logares R. Microbial functional diversity and redundancy: moving forward. *FEMS Microbiol Rev* 2025;49:fuae031. DOI: 10.1093/femsre/fuae031, PMID: 39689915.
- [15] Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. *Nat Rev Immunol* 2013;13(11):790–801. DOI: 10.1038/nri3535, PMID: 24096337.
- [16] Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, *et al.* Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. *Cell* 2018;174(6):1406–1423.e16. DOI: 10.1016/j.cell.2018.08.047, PMID: 30193113.
- [17] Lewandowski R. The gut microbiome as a rainforest: probiotic colonization resistance, functional effects, and next-generation strategies. *FEMS Microbiol Lett* 2026;373:fnag035. DOI: 10.1093/femsle/fnag035, PMID: 41885829.
- [18] Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. *Cell Host Microbe* 2018;23(6):716–724. DOI: 10.1016/j.chom.2018.05.003, PMID: 29902437.
- [19] van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, *et al.* Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013;368(5):407–415. DOI: 10.1056/NEJMoa1205037, PMID: 23323867.
- [20] Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, *et al.* European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017;66(4):569–580. DOI: 10.1136/gutjnl-2016-313017, PMID: 28087657.
- [21] Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, *et al.* Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. *Cell* 2018;174(6):1388–1405.e21. DOI: 10.1016/j.cell.2018.08.041, PMID: 30193112.
- [22] Wu L, Wang XW, Tao Z, Wang T, Zuo W, Zeng Y, *et al.* Data-driven prediction of colonization outcomes for complex microbial communities. *Nat Commun* 2024;15(1):2406. DOI: 10.1038/s41467-024-46766-y, PMID: 38493186.
- [23] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* 2016;165(6):1332–1345. DOI: 10.1016/j.cell.2016.05.041, PMID: 27259147.
- [24] Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* 2016;7(1):22–39. DOI: 10.1080/19490976.2015.1127483, PMID: 26939849.
- [25] Caffrey EB, Sonnenburg JL, Devkota S. Our extended microbiome: The human-relevant metabolites and biology of fermented foods. *Cell Metab* 2024;36(4):684–701. DOI: 10.1016/j.cmet.2024.03.007, PMID: 38569469.
- [26] Amobonye A, Pillay B, Hlope F, Asong ST, Pillai S. Postbiotics: an insightful review of the latest category in functional biotics. *World J Microbiol Biotechnol* 2025;41(8):293. DOI: 10.1007/s11274-025-

04483-8, PMID: 40751848.

- [27] Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, *et al.* Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015;163(5):1079–1094. DOI: 10.1016/j.cell.2015.11.001, PMID: 26590418.
- [28] Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, *et al.* Human postprandial responses to food and potential for precision nutrition. *Nat Med* 2020;26(6):964–973. DOI: 10.1038/s41591-020-0934-0, PMID: 32528151.
- [29] Thaïss CA, Zeevi D, Levy M, Zilberman-Schapira G, Suez J, Tengeler AC, *et al.* Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. *Cell* 2014;159(3):514–529. DOI: 10.1016/j.cell.2014.09.048, PMID: 25417104.
- [30] Lotti S, Dinu M, Colombini B, Amedei A, Sofi F. Circadian rhythms, gut microbiota, and diet: Possible implications for health. *Nutr Metab Cardiovasc Dis* 2023;33(8):1490–1500. DOI: 10.1016/j.numecd.2023.05.009, PMID: 37246076.